The goal of this study is to examine whether measurements of inflammation from brain scanning
and blood tests can predict how much benefit patients with obsessive-compulsive disorder
(OCD) will have from treatment with an anti-inflammatory medication, celecoxib, when adding
to ongoing medication-based treatment for OCD.